Suppr超能文献

“事实是,我们必定会有所遗漏”:一项关于癌症临床试验患者资格筛选过程及自动化前景的定性研究

"The Truth Is, We Must Miss Some": A Qualitative Study of the Patient Eligibility Screening Process, and Automation Perspectives, for Cancer Clinical Trials.

作者信息

La Rosa A, Vaterkowski M, Cuggia M, Campillo-Gimenez B, Tournigand C, Baujat B, Daniel C, Kempf E, Lamé G

机构信息

Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances Pour la e-Santé, LIMICS, Sorbonne University, Inserm, Université Sorbonne Paris Nord, Paris, Cedex, France.

LTSI-UMR 1099, Université de Rennes, CHU de Rennes, Rennes, France.

出版信息

Cancer Med. 2024 Dec;13(23):e70466. doi: 10.1002/cam4.70466.

Abstract

BACKGROUND

Recruitment of cancer patients into clinical trials (CTs) is a challenge. We aimed to explore how patient eligibility assessment is conducted in practice, what factors support or hinder this process, and to assess the potential usefulness of Clinical Trial Recruitment Support Systems (CTRSS) for patient-to-trial matching.

METHODS

We conducted semi-structured interviews in France with healthcare professionals involved in cancer CTs and experts on trial recruitment. We focused on the stages in-between trial feasibility, and patient information and consent. Interviews were recorded, and the transcripts were analyzed thematically. We used the Systems Engineering Initiative for Patient Safety (SEIPS) 2.0 framework to organize our results.

RESULTS

We interviewed 25 participants. We identified common steps for cancer patient eligibility assessment: prescreening under medical supervision, followed by the validation of patient-trial matching based on manual chart review. This process built on rich interactions between clinicians, other professionals (clinical research assistants, data scientists, medical coding experts), and patients. Technological factors, mainly related to data infrastructure (both for patient data and trial data), and organizational factors (research culture, incentives, formal and informal research networks) mediated the performance of the recruitment process. Participants had mixed feelings towards CTRSSs; they welcomed automated pre-screening but insisted on manual verification. Given the necessary collaborative nature of multisite trials, coordinated efforts to support a common data infrastructure could be helpful.

CONCLUSIONS

Material, organizational, and human factors affect cancer patient eligibility assessment for CTs. Patient-to-trial matching tools bear potential, but good understanding of the ecosystem, including stakeholders' motivations, is a prerequisite.

摘要

背景

将癌症患者纳入临床试验是一项挑战。我们旨在探讨在实际操作中如何进行患者资格评估,哪些因素支持或阻碍这一过程,并评估临床试验招募支持系统(CTRSS)在患者与试验匹配方面的潜在效用。

方法

我们在法国对参与癌症临床试验的医疗专业人员和试验招募专家进行了半结构化访谈。我们重点关注试验可行性与患者信息及同意之间的阶段。访谈进行了录音,并对转录本进行了主题分析。我们使用患者安全系统工程倡议(SEIPS)2.0框架来组织我们的结果。

结果

我们采访了25名参与者。我们确定了癌症患者资格评估的常见步骤:在医学监督下进行预筛选,然后基于人工病历审查验证患者与试验的匹配度。这一过程建立在临床医生、其他专业人员(临床研究助理、数据科学家、医学编码专家)和患者之间丰富的互动基础上。技术因素,主要与数据基础设施(患者数据和试验数据)相关,以及组织因素(研究文化、激励措施、正式和非正式研究网络)介导了招募过程的表现。参与者对CTRSS的看法不一;他们欢迎自动化预筛选,但坚持人工核查。鉴于多中心试验所需的协作性质,为支持通用数据基础设施而进行的协调努力可能会有所帮助。

结论

物质、组织和人为因素影响癌症患者参与临床试验的资格评估。患者与试验匹配工具具有潜力,但充分了解包括利益相关者动机在内的生态系统是一个先决条件。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42af/11612666/b2ddd83c1dcd/CAM4-13-e70466-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验